Trial · NCT02514824
Adverse events108
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 108
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 1 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 0 | 5 | |
| other | Agitation | Psychiatric disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | Agitation | Psychiatric disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 | |
| other | Anorexia | Metabolism and nutrition disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 1 | 4 | |
| other | Anorexia | Metabolism and nutrition disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 2 | 5 | |
| other | Bladder spasm | Renal and urinary disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | Bladder spasm | Renal and urinary disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 | |
| other | Confusion | Psychiatric disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | Confusion | Psychiatric disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 2 | 5 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 1 | 4 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 3 | 5 | |
| other | CPK increased | Investigations | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | CPK increased | Investigations | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 | |
| other | Creatinine increased | Investigations | Dose Level 1: MLN01283 3 mg (Phase 1) | 0 | 4 | |
| other | Creatinine increased | Investigations | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 | |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level 1: MLN01283 3 mg (Phase 1) | 1 | 4 | |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level 2: MLN01283 4 mg (Phase 1) | 1 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02514824/events